We are excited to announce our $25 million Series A led by Tal Zaks at @OrbiMed and Anna French at @QimingUS Read more about the news here: altislabs.com/news/altis-lab… The reason this matters was presented in Seoul this week: At the World Conference on Lung Cancer, Johnson & Johnson presented a post-hoc analysis of their Phase 3 MARIPOSA trial, showing that IPRO Response Rate, our AI endpoint, would have detected a significant treatment effect at Week 16… 11 months before the trial's primary efficacy analysis (progression-free survival) and 26 months before its final overall survival analysis. The industry-standard imaging endpoint, objective response rate (ORR), did not anticipate the 12-month survival benefit the drug ultimately delivered, despite ORR being the primary endpoint in 42.6% of oncology drugs approved over the past 5 years. Endpoints set the pace of drug development. An earlier, more reliable read on true clinical benefit lets drug developers stop ineffective therapies sooner and advance effective ones faster, reducing the time between a promising new treatment and the people whose lives depend on it. IPRO reads the entire 3D scan rather than just the diameters of a handful of target lesions, and it is trained on the industry's most comprehensive real-world imaging, clinical, and outcomes database to predict what matters most: survival. Clinical trial sponsors use IPRO in active trials today to generate earlier efficacy signals and inform billion-dollar development decisions. Thank you to our biopharma partners, new and existing investors, and hard-working team for advancing the field to accelerate drug development.